Cholecalciferol
Established medicineAlso known as (+)-vitamin D3, Activated 7-dehydrocholesterol, Animi-3 with Vitamin D, CC+70 more
(+)-vitamin D3, Activated 7-dehydrocholesterol, Animi-3 with Vitamin D, CC, Cal-Quick, Calafol Rx, Calcarb with D, Calcet, Calciol, Caltrate 600 with Iron and Vitamin D, Caltrate Gummy Bites, Caltrate Plus D, Colecalciferol, Colecalciferolum, D-Vi-Sol, D3, D3 + K2, D3 - cholecalciferol, D3 - colecalciferol, D3 Dots, Decalcitrol, Decara, Delta D3, Dialyvite Vitamin D3 Max, Encora AM Tablet, Encora PM Tablet, Folditam, Folgard OS, Folixate, Fosamax Plus D, Infuvite, Infuvite Pediatric, Lactocal, MVC-Fluoride, Maximum D3, Multi-Delyn, Natafort, Nephrocaps QT, Oleovitamin D3, Os-Cal 500 + D, Os-Cal 500 with D, Osteo-Poretical, Ostercal-D, Oysco 500 with D, Oysco D, Poly-Vi-Sol, Poly-Vi-Sol with Iron, PreNexa, ReliOn Glucose, Replesta NX, Thera-D, Tri-Vi-Sol, Tri-Vi-Sol with Iron, VITD - Colecalciferol, VITD - cholecalciferol, Vitafol-One, Vital E- A + D3, Vital E- Newborn, Vital E- Repro, Vitamin D (Cholecalciferol), Vitamin D 3, Vitamin D-3, Vitamin D3, Vitamin D>3<, Vitamin-D3, cholecalciferol (vitamin D3), (5Z,7E)-(3S)-9,10-secocholesta-5,7,10(19)-trien-3-ol, Calcium Carbonate with Vitamin D3, Calcium Citrate with Vitamin D3, Calcium Citrate+D3, Calvite P/D, Cholecalciferolum, Oysco D with Calcium, Viactiv Calcium Plus D.
Recent clinical, regulatory, research and industry developments relating to this drug.
Effect of Vitamin D and Omega-3 Fatty Acids on Blood Pressure and Hypertension
Vitamin D<sub>3</sub> Receptors and Metabolic Enzymes in Hen Reproductive Tissues.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- International journal of molecular sciences2
- Andrology1
- Clinical journal of the American Society of Nephrology : CJASN1
- Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists1
- Journal of the American Society of Nephrology : JASN1
- Amodeo S1
- Argano C1
- Binongo JN1
- Blomberg Jensen M1
- Chandra P1
- Corrao S1
- Grzesiak M1
- Holt R1
- Copenhagen University Hospital - Herlev and Gentofte1
- Copenhagen University Hospital - Rigshospitalet1
- Department of Clinical Medicine1
- Doctoral School of Exact and Natural Sciences1
- Emory University1
- Indiana University School of Medicine1
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Acts on the same molecular target as Cholecalciferol, with 9 overlapping disease areas.
Studied across 8 of the same disease areas as Cholecalciferol in the shared literature.
Studied across 7 of the same disease areas as Cholecalciferol in the shared literature.
Studied across 5 of the same disease areas as Cholecalciferol in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials